2022

Murphy, Gerard, Jayasekera, Geeshath ORCID: https://orcid.org/0000-0003-4061-7569, Mullin, James, Gallagher, Lindsay and Welsh, David J. (2022) Exploring the failing right ventricle in pulmonary hypertension by cardiac magnetic resonance: an in vivo study utilizing Macitentan. Pulmonary Circulation, 12(3), e12124. (doi: 10.1002/pul2.12124) (PMID:36092794) (PMCID:PMC9438403)

2020

Wilson, K. S. et al. (2020) Apoptosis signal-regulating kinase 1 inhibition in in vivo and in vitro models of pulmonary hypertension. Pulmonary Circulation, 10(2), (doi: 10.1177/2045894020922810)

2017

Kurowska-Stolarska, M. et al. (2017) The role of microRNA-155/LXR pathway in experimental and Idiopathic Pulmonary Fibrosis. Journal of Allergy and Clinical Immunology, 139(6), pp. 1946-1956. (doi: 10.1016/j.jaci.2016.09.021) (PMID:27746237) (PMCID:PMC5457127)

2015

Church, Alistair C., Martin, Damien H., Wadsworth, Roger, Bryson, Gareth, Fisher, Andrew J., Welsh, David J. and Peacock, Andrew J. (2015) The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension. American Journal of Physiology: Lung Cellular and Molecular Physiology, 309(4), L333-L347. (doi: 10.1152/ajplung.00038.2015) (PMID:26024891) (PMCID:PMC4538235)

2014

Shao, D. et al. (2014) Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochemical and Biophysical Research Communications, 451(1), pp. 8-14. (doi: 10.1016/j.bbrc.2014.06.111) (PMID:25003325)

2012

Carlin, C., Celnik, D., Pak, O., Wadsworth, R., Peacock, A. and Welsh, D. (2012) Low-dose fluvastatin reverses the hypoxic pulmonary adventitial fibroblast phenotype in experimental pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology, 47(2), pp. 140-148. (doi: 10.1165/rcmb.2011-0411OC)

2009

Weerackody, R. P., Welsh, D. J., Wadsworth, R. M. and Peacock, A. J. (2009) Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction. American Journal of Physiology: Heart and Circulatory Physiology, 296(5), H1312-H1320. (doi: 10.1152/ajpheart.00977.2008)

2008

Dempsie, Y. et al. (2008) Converging Evidence in Support of the Serotonin Hypothesis of Dexfenfluramine-Induced Pulmonary Hypertension With Novel Transgenic Mice. Circulation, 117(22), pp. 2928-2937. (doi: 10.1161/CIRCULATIONAHA.108.767558)

Syyed, R., Reeves, J. T., Welsh, D., Raeside, D., Johnson, M. K. and Peacock, A. J. (2008) The Relationship Between the Components of Pulmonary Artery Pressure Remains Constant Under All Conditions in Both Health and Disease. Chest, 133(3), pp. 633-639. (doi: 10.1378/chest.07-1367)

2007

Carlin, C., Peacock, A. and Welsh, D. (2007) Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 37(4), pp. 447-456. (doi: 10.1165/rcmb.2007-0012OC)

Articles

Murphy, Gerard, Jayasekera, Geeshath ORCID: https://orcid.org/0000-0003-4061-7569, Mullin, James, Gallagher, Lindsay and Welsh, David J. (2022) Exploring the failing right ventricle in pulmonary hypertension by cardiac magnetic resonance: an in vivo study utilizing Macitentan. Pulmonary Circulation, 12(3), e12124. (doi: 10.1002/pul2.12124) (PMID:36092794) (PMCID:PMC9438403)

Wilson, K. S. et al. (2020) Apoptosis signal-regulating kinase 1 inhibition in in vivo and in vitro models of pulmonary hypertension. Pulmonary Circulation, 10(2), (doi: 10.1177/2045894020922810)

Kurowska-Stolarska, M. et al. (2017) The role of microRNA-155/LXR pathway in experimental and Idiopathic Pulmonary Fibrosis. Journal of Allergy and Clinical Immunology, 139(6), pp. 1946-1956. (doi: 10.1016/j.jaci.2016.09.021) (PMID:27746237) (PMCID:PMC5457127)

Church, Alistair C., Martin, Damien H., Wadsworth, Roger, Bryson, Gareth, Fisher, Andrew J., Welsh, David J. and Peacock, Andrew J. (2015) The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension. American Journal of Physiology: Lung Cellular and Molecular Physiology, 309(4), L333-L347. (doi: 10.1152/ajplung.00038.2015) (PMID:26024891) (PMCID:PMC4538235)

Shao, D. et al. (2014) Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochemical and Biophysical Research Communications, 451(1), pp. 8-14. (doi: 10.1016/j.bbrc.2014.06.111) (PMID:25003325)

Carlin, C., Celnik, D., Pak, O., Wadsworth, R., Peacock, A. and Welsh, D. (2012) Low-dose fluvastatin reverses the hypoxic pulmonary adventitial fibroblast phenotype in experimental pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology, 47(2), pp. 140-148. (doi: 10.1165/rcmb.2011-0411OC)

Weerackody, R. P., Welsh, D. J., Wadsworth, R. M. and Peacock, A. J. (2009) Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction. American Journal of Physiology: Heart and Circulatory Physiology, 296(5), H1312-H1320. (doi: 10.1152/ajpheart.00977.2008)

Dempsie, Y. et al. (2008) Converging Evidence in Support of the Serotonin Hypothesis of Dexfenfluramine-Induced Pulmonary Hypertension With Novel Transgenic Mice. Circulation, 117(22), pp. 2928-2937. (doi: 10.1161/CIRCULATIONAHA.108.767558)

Syyed, R., Reeves, J. T., Welsh, D., Raeside, D., Johnson, M. K. and Peacock, A. J. (2008) The Relationship Between the Components of Pulmonary Artery Pressure Remains Constant Under All Conditions in Both Health and Disease. Chest, 133(3), pp. 633-639. (doi: 10.1378/chest.07-1367)

Carlin, C., Peacock, A. and Welsh, D. (2007) Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 37(4), pp. 447-456. (doi: 10.1165/rcmb.2007-0012OC)